Alvotech has raised $300 million through a private bond offering, from which it says net proceeds will be used to fuel continued growth, refinance existing debt and further develop biosimilar assets.    “This successful financing transaction will help fund Alvotech’s plans for future growth and secure the financing of further biosimilar development and clinical studies, the results of which bring significant potential for healthcare providers around the world to drive healthcare savings and ex...